Skip to search.
 TSX Down0.16% TSX Ventures 0.00%

More On SSS.V

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Stem Cell Therapeutics Corp. (SSS.V)

-TSXV
0.38 Up 0.04(10.29%) Apr 21, 3:58PM EDT
Add to Portfolio
ProfileGet Profile for:
Stem Cell Therapeutics Corp.
96 Skyway Avenue
Toronto, ON M9W 4Y9
Canada - Map
Phone: 416-595-0627
Website: http://www.stemcellthera.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:14

Business Summary 

Stem Cell Therapeutics Corp., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Neurogenesis Biotech Corp. and changed its name to Stem Cell Therapeutics Corp. in October 2004. Stem Cell Therapeutics Corp. was founded in 2004 and is headquartered in Toronto, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Stem Cell Therapeutics Corp.

Key Executives 
 PayExercised
Dr. Bjorn Johan Niclas Stiernholm Ph.D.,
Chief Exec. Officer, Pres and Director
20.00k0.00
Mr. James Parsons CA,
Chief Financial Officer
93.00k0.00
Dr. Robert Uger Ph.D.,
Chief Scientific Officer
N/AN/A
Dr. Beverly Incledon Ph.D., 46
VP of Devel.
N/AN/A
Dr. Michael G. Hill Ph.D.,
Head of Calgary Site and Member of the Clinical Advisory Board
N/AN/A
Amounts are as of 2012-12-31 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in CAD.